Jérôme Fayette

13PUBLICATIONS
134CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersTumour immunologySolid tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Oct 01, 2026
Setanaxib Added to Pembrolizumab for Fibroblast-Rich, Recurrent, or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Phase II Randomized Study.

|Mar 12, 2026
Pembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Phase III LEAP-010 Study.

Lisa Licitra, Makoto Tahara, Kevin Harrington

|Jan 22, 2026
Induction Nivolumab Before Chemoradiation in High-Risk Human Papillomavirus-Driven Oropharynx Cancers: IMMUNEBOOST-HPV, a Multicenter Randomized Phase II Trial.

Haitham Mirghani, Anne Aupérin, Caroline Even

|Oct 15, 2025
HERTHENA-PanTumor01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated advanced solid tumors.

Thomas Powles, Aarti Bhatia, Barbara Burtness

|Sep 08, 2025
Randomized clinical efficacy and safety study of peltopepimut-S plus cemiplimab compared to cemiplimab alone in patients with recurrent/metastatic HPV16-positive head and neck cancer.

Caroline Even, Kevin J Harrington, Erminia Massarelli

|Jun 13, 2025
LiGeR-HN phase III trials of petosemtamab + pembrolizumab and petosemtamab monotherapy in recurrent or metastatic HNSCC.

Jean-Pascal Machiels, Jérôme Fayette, Robert Haddad

Pageof 3

Frequent Collaborators

5 joint publications

Lisa Licitra

5 joint publications

Robert I Haddad

5 joint publications

Kevin J Harrington

4 joint publications

Lillian L Siu